Antisense-induced messenger depletion corrects a COL6A2 dominant mutation in ullrich myopathy

Francesca Gualandi, Elisa Manzati, Patrizia Sabatelli, Chiara Passarelli, Matteo Bovolenta, Camilla Pellegrini, Daniela Perrone, Stefano Squarzoni, Elena Pegoraro, Paolo Bonaldo, Alessandra Ferlini

Research output: Contribution to journalArticlepeer-review

Abstract

Collagen VI gene mutations cause Ullrich and Bethlem muscular dystrophies. Pathogenic mutations frequently have a dominant negative effect, with defects in collagen VI chain secretion and assembly. It is agreed that, conversely, collagen VI haploinsufficiency has no pathological consequences. Thus, RNA-targeting approaches aimed at preferentially inactivating the mutated COL6 messenger may represent a promising therapeutic strategy. By in vitro studies we obtained the preferential depletion of the mutated COL6A2 messenger, by targeting a common single-nucleotide polymorphism (SNP), cistronic with a dominant COL6A2 mutation. We used a 2′-O-methyl phosphorothioate (2′OMePS) antisense oligonucleotide covering the SNP within exon 3, which is out of frame. Exon 3 skipping has the effect of depleting the mutated transcript via RNA nonsense-mediated decay, recovering the correct collagen VI secretion and restoring the ability to form an interconnected microfilament network into the extracellular matrix. This novel RNA modulation approach to correcting dominant mutations may represent a therapeutic strategy potentially applicable to a great variety of mutations and diseases.

Original languageEnglish
Pages (from-to)1313-1318
Number of pages6
JournalHuman Gene Therapy
Volume23
Issue number12
DOIs
Publication statusPublished - Dec 1 2012

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics

Fingerprint Dive into the research topics of 'Antisense-induced messenger depletion corrects a COL6A2 dominant mutation in ullrich myopathy'. Together they form a unique fingerprint.

Cite this